JP2022532865A5 - - Google Patents
Info
- Publication number
- JP2022532865A5 JP2022532865A5 JP2021564704A JP2021564704A JP2022532865A5 JP 2022532865 A5 JP2022532865 A5 JP 2022532865A5 JP 2021564704 A JP2021564704 A JP 2021564704A JP 2021564704 A JP2021564704 A JP 2021564704A JP 2022532865 A5 JP2022532865 A5 JP 2022532865A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025013168A JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962843190P | 2019-05-03 | 2019-05-03 | |
| US62/843,190 | 2019-05-03 | ||
| US201962855828P | 2019-05-31 | 2019-05-31 | |
| US62/855,828 | 2019-05-31 | ||
| US201962868262P | 2019-06-28 | 2019-06-28 | |
| US62/868,262 | 2019-06-28 | ||
| US201962931669P | 2019-11-06 | 2019-11-06 | |
| US62/931,669 | 2019-11-06 | ||
| US201962944903P | 2019-12-06 | 2019-12-06 | |
| US62/944,903 | 2019-12-06 | ||
| PCT/US2020/031231 WO2020227177A1 (en) | 2019-05-03 | 2020-05-03 | Methods of administering chimeric antigen receptor immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013168A Division JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532865A JP2022532865A (ja) | 2022-07-20 |
| JP2022532865A5 true JP2022532865A5 (https=) | 2023-05-15 |
| JPWO2020227177A5 JPWO2020227177A5 (https=) | 2023-05-15 |
Family
ID=73050885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564704A Pending JP2022532865A (ja) | 2019-05-03 | 2020-05-03 | キメラ抗原受容体免疫療法の投与方法 |
| JP2025013168A Pending JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013168A Pending JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200384027A1 (https=) |
| EP (2) | EP4249075A3 (https=) |
| JP (2) | JP2022532865A (https=) |
| KR (1) | KR20220005075A (https=) |
| CN (3) | CN118662516A (https=) |
| AU (2) | AU2020267378B2 (https=) |
| BR (1) | BR112021021996A2 (https=) |
| CA (1) | CA3138707A1 (https=) |
| IL (1) | IL287533A (https=) |
| MX (1) | MX2021013394A (https=) |
| SG (1) | SG11202112123RA (https=) |
| TW (1) | TW202108150A (https=) |
| WO (1) | WO2020227177A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200384027A1 (en) * | 2019-05-03 | 2020-12-10 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| US20220184208A1 (en) * | 2020-12-04 | 2022-06-16 | Morphosys Ag | Anti-cd19 combination therapy |
| WO2022137186A1 (en) * | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
| EP4271817A2 (en) | 2020-12-30 | 2023-11-08 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| CN113406334A (zh) * | 2021-06-02 | 2021-09-17 | 浙江省人民医院 | 一种dlbcl相关的生物标记组合物及其应用、dlbcl预后的效果预测模型 |
| US20230268031A1 (en) * | 2021-07-30 | 2023-08-24 | Kite Pharma, Inc. | Monitoring and management of cell therapy-induced toxicities |
| CN113786490A (zh) * | 2021-09-14 | 2021-12-14 | 华中科技大学同济医学院附属协和医院 | 能调控巨噬细胞表观遗传的制剂用于制备治疗噬血细胞综合征药物的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| CA2147466A1 (en) | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| NZ609201A (en) * | 2010-10-27 | 2015-01-30 | Amgen Res Munich Gmbh | Means and methods for treating dlbcl |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| WO2013040557A2 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| JP2017505819A (ja) | 2014-02-04 | 2017-02-23 | カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ | Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物 |
| IL295224B2 (en) | 2015-05-28 | 2025-07-01 | Kite Pharma Inc | Methods of conditioning patients for t cell therapy |
| EP3364969A4 (en) | 2015-10-20 | 2019-07-10 | Kite Pharma, Inc. | METHOD FOR THE PRODUCTION OF T CELLS FOR T CELL THERAPY |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| US20190336504A1 (en) * | 2016-07-15 | 2019-11-07 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| SG10201912400VA (en) * | 2017-04-24 | 2020-02-27 | Kite Pharma Inc | Humanized antigen-binding domains against cd19 and methods of use |
| AU2018275894B2 (en) * | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| EP3691663A4 (en) * | 2017-10-02 | 2021-08-18 | Humanigen, Inc. | METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST |
| CA3084470A1 (en) * | 2017-10-18 | 2019-04-25 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| US20200384027A1 (en) * | 2019-05-03 | 2020-12-10 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
-
2020
- 2020-05-03 US US16/865,369 patent/US20200384027A1/en not_active Abandoned
- 2020-05-03 SG SG11202112123RA patent/SG11202112123RA/en unknown
- 2020-05-03 CN CN202410645821.4A patent/CN118662516A/zh active Pending
- 2020-05-03 CN CN202410645866.1A patent/CN118593691A/zh active Pending
- 2020-05-03 BR BR112021021996A patent/BR112021021996A2/pt unknown
- 2020-05-03 CN CN202080043985.XA patent/CN114206346A/zh active Pending
- 2020-05-03 KR KR1020217039585A patent/KR20220005075A/ko not_active Ceased
- 2020-05-03 MX MX2021013394A patent/MX2021013394A/es unknown
- 2020-05-03 EP EP23186520.5A patent/EP4249075A3/en active Pending
- 2020-05-03 EP EP20801592.5A patent/EP3962490A4/en not_active Withdrawn
- 2020-05-03 AU AU2020267378A patent/AU2020267378B2/en active Active
- 2020-05-03 CA CA3138707A patent/CA3138707A1/en active Pending
- 2020-05-03 JP JP2021564704A patent/JP2022532865A/ja active Pending
- 2020-05-03 TW TW109114736A patent/TW202108150A/zh unknown
- 2020-05-03 WO PCT/US2020/031231 patent/WO2020227177A1/en not_active Ceased
-
2021
- 2021-10-24 IL IL287533A patent/IL287533A/en unknown
-
2023
- 2023-02-10 US US18/167,725 patent/US20230270785A1/en active Pending
-
2025
- 2025-01-29 JP JP2025013168A patent/JP2025069275A/ja active Pending
- 2025-04-30 AU AU2025203054A patent/AU2025203054A1/en active Pending